HGS Anticipates Broad SLE Patient Access For Benlysta
This article was originally published in The Pink Sheet Daily
Executive Summary
With launch just underway of its newly approved lupus drug, HGS is seeing encouraging signs early on from payers.
You may also be interested in...
The Cabilly Saga: New Patent, New Product, New Lawsuits
Genentech seeks Benlysta royalties from HGS and GSK through enforcement of the Cabilly III patent.
The Cabilly Saga: New Patent, New Product, New Lawsuits
Genentech seeks Benlysta royalties from HGS and GSK through enforcement of the Cabilly III patent.
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.